Corporate Responsibility
Health and Wellness
Diversity and Inclusion
Education & Awareness
Seeing Brown, Blue, Green, and Every Color in Between
closer look at the science behind eye color.
Foundation Supports Medical Missions
 To Restore Sight and Train Eye Care Providers
Novartis announces intention to spinoff Transaction would create world leading eye care devices company.
Corporate Responsibility
Eye Care for Everyone
R&and Manufacturing Facilities
Community Partnership Day
Announces Acquisition of Tear Film Innovations, Inc.
Appoints Roger Lopez as Region President Japan as Jim Murphy Retires After Nearly 25-Years with Company
Introduces New Medical Affairs Website in North America, Expanding Support for Patient Care and Clinical Community
Supports Future Leaders of Ophthalmology With Launch of Retina Fellows Institute
has one mission: to provide innovative products that enhance quality of life by helping people see better.
CyPass® Micro-Stent Market Withdrawal
Information and resources for healthcare professionals.
Content is intended for a global audience
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
Enhancing Quality of Life by Helping People See Better
As the global leader in eye care, develops and manufactures innovative medicines and devices to serve the full life cycle of eye care needs.
Corporate Responsibility
As the global leader in eye care, we take our corporate responsibilities seriously, and continually strive to do the right thing for our customers and their patients, our company, our employees, our stakeholders and our communities.
has more than 20,000 associates in 74 countries, collectively working to provide innovative products that enhance quality of life by helping people see better.
welcomes your questions and comments.
Content is intended for a global audience
Cookies are small text files that are sent to your computer when you visit a website. Cookies on Novartis Group company (Novartis) web sites do lots of different jobs, like letting you navigate between pages efficiently, storing your preferences and generally improving your experience of a website.
The Directive 2009/136/states that we can store cookies on your machine, if they are essential to the operation of this site, but that for all others we need your permission to do so.
Novartis sites can use some non-essential cookies. We do not do this to track individual users or to identify them, but to gain useful knowledge about how the sites are used so that we can keep improving them for our users. Without the knowledge we gain from the systems that use these cookies we would not be able to provide the service we do.
If you decide to set the language, font-size or specific version of the site (e.g. high-contrast), we use “user interface customization cookies”. Once set, you do not need to specify your preferences again on another visit to the site.
If you use parts of the site that require registration to access content, we will place an “authentication cookie” on your computer. This allows you to leave and return to these parts of the site without re-authenticating yourself.
If you have Adobe Flash installed on your computer (most computers do) and you use video players, we store a “flash cookie” on your computer. These cookies are used to store data needed to play back video or audio content and store the user’s preferences.
Novartis likes to understand how visitors use our websites by using web analytics services. They count the number of visitors and tell us things about the visitors’ behaviour overall – such as identifying the search engine keywords that lead the user to the site, the typical length of stay on the site or the average number of pages a user views. For this purpose we place a “first party analytics cookie” on your computer.
We may also use services such as Google Analytics to track web statistics. In this case, Google will place a “3rd party cookie” on your computer. This is also the case when we use Google Maps.
Any data collected by using these cookies will be stored and managed by Novartis or one of its trusted affiliates in countries Novartis operates in.
For more information or how to contact Novartis, please refer to the  Novartis Data Privacy Policy .
If you don’t want to receive cookies, you can modify your browser so that it notifies you when cookies are sent to it or you can refuse cookies altogether. You can also delete cookies that have already been set.
If you wish to restrict or block web browser cookies which are set on your device then you can do this through your browser settings; the Help function within your browser should tell you how. Alternatively, you may wish to visit  www.aboutcookies.org (link is external) , which contains comprehensive information on how to do this on a wide variety of desktop browsers.Navigation
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
welcomes your questions and comments.
 Please select a topic from the list below. If none of the links relates to your question, please select Other / general inquiry below or call one of the telephone numbers found on this page.
Product quality concern or report an adverse event
Problems redeeming a coupon or rebate offer
Information for health care professionals
Careers and partnerships
Learn about working at Become an associate
Internships and co-op opportunities
Other / general inquiry
By clicking "Yes" you acknowledge and agree to policy regarding the use and sharing of your personal data. For more information, please see our
United States
Consumer Care Team
For information about products or medical data
Content is intended for a global audience
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
Helping People See Better
has one mission: to provide innovative products that enhance quality of life by helping people see better.
Commitment to Patients
is helping people see the world better through advanced surgical and vision care products.
Alcon's leadership is grounded in cutting-edge innovation and breakthrough technology, transforming the way we treat eye diseases and conditions.
Executive Leadership Team
The leadership team drives us to do what we do best. Learn about our Executive Leadership Team and their dedication to and its mission.
was founded in 1945 as a small ophthalmic shop in Fort Worth, Texas.
Bintou’s Life is Whole Again
Pure Joy – The Mercy Vision Program
Elevating Vision Care
We’re driven to find solutions for the world’s most pressing eye care needs.
Content is intended for a global audience
At Alcon, we recognize that our success depends on the creativity, dedication and performance of our associates. That’s why we foster a performance-oriented culture that encourages achievement through collaboration and innovation . This culture is reflected in our product pipeline , one of the most exciting in the industry today. We depend on our diverse and talented associates to bring a full spectrum of innovative medicines and devices to patients that address their eye care needs, creating one of the most rewarding work environments in our industry.
Health and Wellness
ensures each employee has the tools and resources necessary to achieve their personal health and wellness goals.
associates engage worldwide to improve eye care on a local level through service projects and community-based volunteer activities.
Diversity and Inclusion
Diversity helps drive Alcon’s innovation .  As our customer base becomes increasingly diverse, employing individuals with a variety of backgrounds becomes critical in being able to better understand patient and customer needs, and provide innovative solutions.
We value the differences amongst our associates, including race, ethnicity, religion, gender, age, sexual orientation and disability. This extends to inclusive leadership and teamwork, an essential component of our collaborative culture. By enabling individuals and groups to contribute their unique perspectives, we are allowing for more creative ideas and better solutions.
Diversity and inclusion add value not only for our associates, but also for our patients, customers, shareholders, and the communities in which we live and work.
Life at combines a dynamic, positive work environment with our commitment to helping people see better.Navigation
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
New Corporate Responsibility
Leading the Way in Eye Care
Eye Care for Everyone
As the global leader in eye care, is committed to helping people see better.
Responsible Business Practices
At Alcon, we want to ensure that innovative eye care products are within reach of those who need them.
seeks to continually identify and partner with best-in-class diverse suppliers.
Education & Awareness
World Glaucoma Week: Don’t Miss Life’s Moments
Bintou’s Life is Whole Again
Recovering from Blindness
Enhancing Sight. Enhancing Lives.
Partners in Eye Care
Quality & Safety Standards
We’re driven to find solutions for the world’s most pressing eye care needs.
Content is intended for a global audience
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
We have one mission: to provide innovative products that enhance quality of life by helping people see better. Together with 
, we offer the widest spectrum of products in eye care. This enables us to serve our customers through the full life cycle of patient needs across eye diseases, vision conditions and refractive errors.
The Novartis Declaration for Patients spells out our commitments in five areas, from safety to clinical trials.
Our vision is to be the most trusted leader in eye care. By serving and working with people worldwide, we are building our reputation, while addressing the growing eye care demands of the future.
Content is intended for a global audience
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
Community Partnership Day
Community Partnership Day (CPD), our annual day of volunteering, unites associates from across all Novartis divisions for one common goal - to strengthen our communities. Volunteering on gives us the opportunity to connect with one another, with our neighbors and with causes that matter to us. On CPD, our collective impact makes a difference in the lives of people in need.
Foundation Supports Medical Missions
Mercy Ships: Bringing hope and healing
Volunteers Help Prepare Inmates for Post-release Employment
Content is intended for a global audience
Corporate Responsibility
Health and Wellness
Diversity and Inclusion
New Eye Care for Everyone
Enhance Sight and Improve Lives 
Poor vision keeps individuals from achieving their potential and living full, independent lives.
Partners in Eye Care
shares long-standing relationships with humanitarian organizations around the world.
Emerging Markets
Building sustainable eye care in emerging markets, such as China, India and Russia, is a key priority for Alcon.
Commitment to Education
Expanding access to quality eye care is impossible without first expanding access to education and hands-on training.
Bintou’s Life is Whole Again
Pure Joy – The Mercy Vision Program
Elevating Vision Care
Quality & Safety Standards
We’re driven to find solutions for the world’s most pressing eye care needs.
Content is intended for a global audience
is the global leader in the highly attractive and growing $23 billion eye care devices market
Market leading development capabilities and innovation investments
Clearly defined near and long-term strategy, focused on sales growth, operational excellence and free cash flow generation
20,000+ employees dedicated to eye care, with a strong and experienced management team
Disciplined capital allocation strategy outlined
New York, November 27, 2018 — Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of Novartis to execute a tax-neutral, 100% spinoff of the business. If the transaction proceeds, shares in Inc. will be listed on the Swiss Exchange (SIX) and the New York Stock Exchange (NYSE) under the ticker symbol “ALC”.  Watch the webcast (link is external)
Chairman-designate, Mike Ball and CEO, David Endicott, will be joined by other senior management to discuss Alcon’s strengths and how the company is positioned to win in the large, attractive and growing eye care devices market, where it is already the global leader. They will present Alcon’s vision and strategy, near- and longer-term growth drivers, five-year financial goals and the benefits of as a standalone company.
Mike Ball, Chairman-designate of Alcon, said: “has been a leader in the ophthalmic industry for over 70 years and is dedicated to providing innovative products that enhance quality of life by helping people see better. More recently, has executed a turnaround plan that has reinvigorated its pipeline, strengthened its customer relationships, and increased investments in promotion, capital and systems while developing a nimble medical device culture. These actions have strengthened its foundation and positioned well to become a standalone company.” 
David Endicott, of Alcon, said: “As the leading eye care devices company in the world, with $6.8 billion in sales in 2017, we are uniquely positioned to succeed as a standalone organization. Our legacy of industry firsts and advancements, our leading positions in the markets we operate in and our substantial investment in innovation position us well for the future. We look forward to sharing our strategy, vision and financial goals with investors and analysts at our Capital Markets Day events.”
Mega-trends shape future of eye care
will highlight mega-trends shaping the future of eye care, including the aging global population, innovation that improves patient options and outcomes, increasing wealth and growth in emerging economies, and the prevalence of myopia and digital eye strain. These trends present with sizeable growth opportunities in the $23 billion eye care devices market. will also showcase its leading ocular solutions for refractive disorders, presbyopia, dry eye, cataracts and retinal diseases.
David Murray will highlight how has returned to a position of strength by delivering consecutive quarters of sales growth, and how the company plans to make steady core operating margin improvements to industry benchmark levels, from high teens today to low to mid 20s by 2023. Post-spinoff, is targeting an investment grade credit rating and will have a financial framework focused on sales growth, operational excellence and free cash flow generation. Priorities will include investment in organic growth and R&D, a disciplined focus on “bolt-on” acquisition, licensing and collaboration opportunities, and returns to shareholders with expecting to pay a regular cash dividend from 2020.
Michael Onuscheck, President Global Business & Innovation, will highlight Alcon’s market leadership in its Surgical Franchise, with 2017 global sales of $3.7 billion. He will highlight strong fundamentals, including world class customer focus, a leading portfolio of in-market innovations and a strong pipeline. He will also discuss Alcon’s best-in-class equipment platforms and the expansion potential of its leading installed base and complementary consumables business, as well as key near-term growth drivers such as advanced technology intraocular lenses (AT-IOLs) and leading-edge vitreoretinal technologies.
Andy Pawson, President & General Manager, Global Vision Care Franchise, will provide an overview of as one of the leaders in the $14 billion vision care market, with 2017 global sales of $3.1 billion. Key trends in contact lenses include the shift from reusable to daily disposable lenses and increasing demand for premium lenses such as toric, multifocal and cosmetic. In ocular health, increased awareness of treatment options for dry eye is driving demand. He will also discuss near-term growth drivers, which are the TOTAL1 contact lens portfolio and its market-leading dry eye treatment, SYSTANE.
The executive team will also discuss their expectations for the primary drivers of longer term vision care and surgical growth. These include the acceleration of innovation, expansion into new markets and adjacencies, as well as new business models and go-to-market solutions, which better serve the needs of eye care professionals, patients and consumers.
Franck Leveiller, Senior Vice President, Head of Global R&D, will discuss Alcon’s aspiration to lead the world in eye care innovation. He will highlight Alcon’s history of industry firsts, positioning as the partner of choice for external innovation, and continued commitment to R&investment resulting in a pipeline fueled for growth. He will discuss Alcon’s world-class capabilities in optics, material and surface chemistry, equipment and instrumentation, and automation, which is already delivering improved cycle times, increased flexibility and productivity enhancements.
Spinoff completion subject to approvals and conditions being met
Completion of the planned spinoff is subject to general market conditions, receipt of necessary authorizations, tax rulings and opinions, final endorsement by the Board of Directors of Novartis and shareholder approval at the Novartis annual shareholder meeting on February 28, 2019. If approvals are secured and conditions are met, the spinoff is expected to be completed in the first half of 2019.
The background slide deck will be available on Tuesday November 27, 2018.
Alcon’s next Capital Markets Day will be in London on December 4, 2018.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “to highlight,” “vision,” “strategy,” “focused on,” “intention,” “will,” “strengths,” “growing,” “growth drivers,” “goals,” “dedicated,” “turnaround plan,” “pipeline,” “to become,” “positioned,” “future,” “look forward,” “mega-trends,” “increasing,” “emerging,” “growth opportunities,” “targeting,” “priorities,” “focus,” “portfolio,” “potential,” “aspiration,” “commitment,” “subject to,” “planned,” “expected,” “initial,” “proposed,” “plans,”  “strategic benefits,” “expectations,” “driving,” “drivers,” or similar expressions, or by express or implied discussions regarding the potential completion of the announced spinoff of Alcon; regarding whether the spinoff is in the best interests of shareholders, regarding the future commercial performance of Novartis or a standalone company, or regarding any potential strategic benefits, synergies or opportunities as a result of the spinoff; or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward looking statements. There can be no guarantee that the proposed spinoff will be completed in the expected form or within the expected time frame or at all.  Neither can there be any guarantee that Novartis or a standalone company will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of the spinoff or any related actions, within any particular time frame, or at all. Nor can there be any guarantee that shareholders of Novartis or will achieve any particular level of shareholder returns. Neither can there be any guarantee that the spinoff of will be in the best interests of shareholders, or that the Novartis Group or any of its divisions, or a standalone company, will be commercially successful in the future, or achieve any particular credit rating or financial results. In particular, our expectations could be affected by, among other things: an unexpected failure to satisfy the required conditions to the proposed spinoff, or to obtain the shareholder and other approvals needed to complete these actions, or unexpected delays in meeting these requirements; the potential that the strategic benefits, synergies or opportunities expected from the proposed spinoff may not be realized or may take longer to realize than expected; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or government regulation generally; the inherent uncertainties involved in predicting shareholder returns; the successful separation of the business from the Novartis Group; potential adverse reactions to the proposed transaction by customers, suppliers, strategic partners or key personnel and potential difficulties in maintaining relationships with such persons; the uncertainties inherent in the and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; the ability of as a standalone company to obtain or maintain proprietary intellectual property protection; safety, quality or manufacturing issues, including withdrawal of products from the market; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally; uncertainties involved in the development or adoption of potentially transformational technologies and business models; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products or those of as a standalone company; and uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems or those of as a standalone company; and other risks and factors referred to in Novartis AG’s current Form 20-on file with the Securities and Exchange Commission (SEC) or in the initial Form 20-filed by with the Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
This press release is not an offer to sell, or a solicitation of an offer to buy or sell, any securities of Novartis or, following the proposed spinoff, of Alcon, and may not be relied upon in connection with the purchase or sale of any such security. Should you wish to invest in Alcon, you should do so solely on the basis of information will file with the at or around the time of the spinoff, including the section “Risk Factors” included in the Form 20-The information filed with the will be available on the SEC’s website at www.sec.gov (link is external) .
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com (link is external) .
is the global leader in eye care devices. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our products touch the lives of more than 260 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. Learn more at www.alcon.com (link is external).
